Biovail Submits Complete Response to FDA for BVF-033

    TORONTO, October 24 /CNW/ - Biovail Corporation (NYSE:  BVF) (TSX:BVF)
announced today that the Company has submitted a Complete Response to the
United States Food and Drug Administration (FDA) that addresses all the issues
raised in the Non-Approval Letter for BVF-033, a novel once-daily salt
formulation of bupropion.

    Based on Biovail's discussions with the FDA in an August 14, 2007
meeting, and in accordance with FDA feedback, the submission includes new
analyses of the data included in the original New Drug Application (NDA) for
BVF-033, but does not include results from any new studies. Biovail
anticipates receiving a response from the FDA in the near term. The Company
believes the data package is sufficient to support the approval of BVF-033.

    "Safe Harbor" Statement Under the Private Securities Litigation Reform
Act of 1995

    To the extent any statements made in this press release contain
information that is not historical, these statements are forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as amended,
and within the meaning of the "safe harbor" provisions of applicable Canadian
securities legislation. These forward-looking statements relate to, among
other things, our intentions and plans, and can generally be identified by the
use of words such as "believes" and "anticipates", and other similar
expressions. Although Biovail believes that the expectations and intentions
reflected in such forward-looking statements are reasonable, such statements
involve risks and uncertainties, and undue reliance should not be placed on
such statements. Specifically the risks and uncertainties the Company faces
include, but are not limited to, the uncertainties related to the regulatory
process, including regulatory approval. Additional information about these
factors may be found in the body of this news release, and under the heading
"Risk Factors" contained in Item 3(D) of Biovail's most recent Annual Report
on Form 20-F/A.

    About Biovail Corporation

    Biovail Corporation is a specialty pharmaceutical company, engaged in the
formulation, clinical testing, registration, manufacture, and
commercialization of pharmaceutical products utilizing advanced drug-delivery
technologies. For more information about Biovail, visit the Company's Web site

    For further information, please contact Nelson F. Isabel at 905-286-3000
or send inquiries to

For further information:

For further information: Biovail Corporation Nelson F. Isabel,
905-286-3000 Vice-President, Investor Relations and Corporate Communications

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890